8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 1, 2026·SEC
Celcuity Inc.(CELC)Earnings, Financials & Key Ratios
CELC•NASDAQ
$115.72
Price updated Jul 7, 2026
AboutCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.Show more
- Revenue$0
- EBITDA-$172M-52.1%
- Net Income-$177M-58.4%
- EPS (Diluted)-3.78-33.6%
- ROE-163.8%-87.1%
CELC Price & Volume
Celcuity Inc. (CELC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Significant Equity Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial outcome
Key Thesis Takeaways
- Celcuity remains a high-risk, pre-revenue biotechnology entity whose valuation is entirely contingent upon the successful clinical outcomes of the VIKTORIA Phase 3 trial for Gedatolisib.
- The company faces substantial financial pressure as it navigates an accelerating cash burn trajectory, with quarterly R&D expenditures reaching $33.1 million in 2026Q1.
- Investors should monitor the firm's ability to manage its $195.6 million debt load, as the lack of commercial revenue necessitates ongoing capital market reliance to sustain operations.
Verdict Logic
the company's reliance on external financing to cover a $55.3 million quarterly free cash flow deficit creates significant dilution risk for shareholders.
CELC Growth Metrics
Celcuity Inc. (CELC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-51.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-28.38%
Return on Capital
10 Years-46.03%
5 Years-48.26%
3 Years-50.16%
Last Year-54.16%
CELC Recent Earnings
Celcuity Inc. (CELC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.97+6.7%
$1.04
Rev
—
$3M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.97+8.5%
$1.06
Rev
—
$1M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.92+9.8%
$1.02
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.04-15.6%
$0.90
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.97vs $1.04+6.7% | —vs $3M |
| Q2 2026 | Mar 25, 2026 | $0.97vs $1.06+8.5% | —vs $1M |
| Q4 2025 | Nov 12, 2025 | $0.92vs $1.02+9.8% | — |
| Q3 2025 | Aug 14, 2025 | $1.04vs $0.90-15.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Celcuity Inc. (CELC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $115.72 | $5.64B | -30.61 | — | — | -163.8% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $30.12 | $3.5B | -34.62 | 48.29% | -188.15% | -41.54% | — | |
| $1.24 | $66.13M | -0.84 | — | — | -68.98% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — |
Compare CELC vs Peers
Celcuity Inc. (CELC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELC SEC Filings & Documents
Celcuity Inc. (CELC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CELC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CELC Frequently Asked Questions
Celcuity Inc. (CELC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CELC profitable?
Celcuity Inc. (CELC) reported a net loss of $192.9M for fiscal year 2025.
Dividend & Returns
What is CELC's return on equity?
Celcuity Inc. (CELC) has a return on equity (ROE) of -163.8%. Negative ROE indicates the company is unprofitable.
What is Celcuity Inc.'s free cash flow?
Celcuity Inc. (CELC) had negative free cash flow of $172.9M in fiscal year 2025, likely due to heavy capital investments.